SEC Form 4 · accession 0001681871-17-000010

Bausch Health Companies Inc. · BHC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP, CHIEF ACCOUNTING OFFICER

Period of report

Jan 6, 2017

Accepted (ET)

Mar 3, 2017 · 6:27 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000885590

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, no par value^F1	Jan 6, 2017	A	12,799	$0.00	A	66,590	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restricted Share Units^F2	—	Jan 6, 2017	A	8,534	A	—	Jan 6, 2020	Common Stock	8,534	8,534	D
Non-Qualified Stock Options (right to purchase)^F3	$14.38	Mar 1, 2017	A	31,430	A	—	Mar 1, 2027	Common Shares, no par value	31,430	31,430	D

F1Represents the award of restricted share units (RSUs) which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant").
F2Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 4,267 and the maximum number that can be distributed is 8,534. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's total shareholder return (TSR) as measured on January 6, 2020 (the Measurement Date). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award.
F3The options vest in equal installments on each of the first three anniversaries of the date of grant.